FAUC 299 | 313972-96-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: FAUC 299
• 英文别名: 1H-Indole-5-carbonitrile, 2-((4-phenyl-1-piperazinyl)methyl)-；2-[(4-phenylpiperazin-1-yl)methyl]-1H-indole-5-carbonitrile
• CAS: 313972-96-2
• 化学式: C₂₀H₂₀N₄
• 分子量: 316.406
• InChiKey: TWVIJESEEXGVPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  46.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-(tert-butyldimethylsilanyloxymethyl)indole-5-carbonitrile 在 四氯化碳 、 polymer-bound 3-benzyloxypropane-1,2-diol 、 四丁基氟化铵 、 对甲苯磺酸 、 三苯基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 71.0h， 生成 FAUC 299
  参考文献：
  名称：

  Cyanoindole Derivatives as Highly Selective Dopamine D₄ Receptor Partial Agonists:  Solid-Phase Synthesis, Binding Assays, and Functional Experiments

  摘要：

  Traceless linking of diethoxymethyl (DEM)-protected 5- and 6-cyanoindoles and subsequent incorporation of phenylpiperazine derivatives led to the 2- and 3-piperazinylmethyl-substituted cyanoindoles 3a-m. Dopamine receptor binding studies on the final products 3a-m clearly indicated strong and selective recognition of the D-4 subtype which is known as a promising target for the treatment of neuropsychiatric disorders. The most interesting binding properties were observed for the 2-aminomethyl-5-cyanoindoles FAUC 299 (3f) and FAUC 316 (3j) (K-i = 0.52 and 1.0 nM, respectively) when the fluoro derivative 3j proved extraordinary selectivity over D-1, D-2long, D-2short, and D-9 (>8600). To determine ligand efficacy, mitogenesis experiments were performed indicating partial agonist effects for the test compounds 3fj (35% and 30%, when compared to the full agonist quinpirole).

  DOI：

  10.1021/jm0009989

文献信息

• VERFAHREN ZUR HERSTELLUNG VON INDOLDERIVATEN AN FESTER PHASE
  申请人：MERCK PATENT GmbH

  公开号：EP1222167A2

  公开（公告）日：2002-07-17
• METHOD OF TREATMENT FOR MENTAL DISORDERS
  申请人：IKEDA Kazuhito

  公开号：US20120115879A1

  公开（公告）日：2012-05-10

  The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D 4 receptor agonist.
• US8258139B2
  申请人：——

  公开号：US8258139B2

  公开（公告）日：2012-09-04
• US9259423B2
  申请人：——

  公开号：US9259423B2

  公开（公告）日：2016-02-16
• US9827242B2
  申请人：——

  公开号：US9827242B2

  公开（公告）日：2017-11-28